Superworth

Cognition Therapeutics free cash flow CGTX

Cash from operations less capital spending, by quarter and over the last twelve months, from 2020.

Last 12 months, to Dec 31, 2024
n/m
a quarter missing
Latest quarter, Q4 FY24
−$8.4M
Fiscal year 2024
n/a

Cognition Therapeutics' twelve-month free cash flow can't be added up yet: a quarter of its results is missing from our data.

In its latest quarter, Q4 FY24, it was −$8.4M.

Free cash flow over time

Open the interactive chart, with overlays and comparisons

Fiscal year by fiscal year

Fiscal yearFree cash flowChange
FY2024n/an/a
FY2023−$16.2Mn/a
FY2022−$18.7Mn/a
FY2020n/an/a

Each fiscal year is the twelve months to its fourth quarter.

Quarter by quarter

QuarterEndedFree cash flowOn a year earlierLast 12 months
Q4 FY24−$8.4Mn/an/a
Q3 FY24−$6.9Mn/an/a
Q4 FY23−$5.5Mn/a−$16.2M
Q3 FY23−$4.2Mn/a−$20.9M
Q2 FY23−$3.7Mn/a−$16.7M
Q1 FY23−$2.7Mn/a−$18.3M
Q4 FY22−$10.2Mn/a−$18.7M
Q3 FY22−$27Kn/an/a
Q2 FY22−$5.4Mn/an/a
Q1 FY22−$3.1Mn/an/a
Q4 FY20−$480Kn/an/a

Against its peers

Companies in Healthcare nearest Cognition Therapeutics' size, closest first, today.

CompanyFree cash flow yield
CGTXCognition Therapeuticsn/m
SPROSpero Therapeuticsn/m
LFVNLifevantage9.1%
APTAlpha Pro Tech10.3%
ICCCImmucell4.5%
KEQUKewaunee Scientific11.5%
ATNMActinium Pharmaceuticalsn/m
NEPHNephrosn/m
PDEXPro DEX3.4%
PLXProtalix BioTherapeutics3.7%
NATRNatures Sunshine Products8.5%
Peer median8.5%

What the free cash flow tells you

Cash from operations minus capital spending. The cash the company could hand back or reinvest.

Seasonal and lumpy quarter to quarter. The TTM view is the one to trust.

More on Cognition Therapeutics

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.